Los puntos clave no están disponibles para este artículo en este momento.
Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
Kratochwil et al. (Thu,) studied this question.